Clinical Trial Update: Muscadine Plus (MPX) In Men With Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of Muscadine Plus (MPX) in men with prostate cancer was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Prostate Cancer

Drugs mentioned

• Muscadine Plus (MPX)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Adenocarcinoma of the Prostate | Phase 3 | Status: TERMINATED | Results posted: 2023-05-22